Immunization strategies to augment oral vaccination with DNA and viral vectors expressing HIV envelope glycoprotein

Vaccine

Volumn 20, Issue 9-10, 2002, Pages 1295-1307

  Wierzbicki, Andrzej ^a   Kiszka, Irena ^b   Kaneko, Hiroshi ^a   Kmieciak, Dariusz ^c   Wasik, Thomas J ^a   Gzyl, Jaroslaw ^c   Kaneko, Yutaro ^d   Kozbor, Danuta ^a,c  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c TEMPLE UNIVERSITY   (United States)

^d AJINOMOTO CO INC   (Japan)

Author keywords

HIV; Oral immunization; Vaccine

Indexed keywords

BETA GLUCAN; DNA; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYBRID PROTEIN; IMMUNOGLOBULIN; LENTINAN; LIPOSOME; PLASMID DNA; PRIMER DNA; RECOMBINANT INTERLEUKIN 2; RETROVIRUS VECTOR; VIRUS GLYCOPROTEIN;

ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DNA VECTOR; DRUG EFFECT; DRUG EFFICACY; EXPRESSION VECTOR; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOMODULATION; MICROENCAPSULATION; MOUSE; MOUTH MUCOSA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS ENVELOPE;

ADMINISTRATION, ORAL; AIDS VACCINES; ANIMALS; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP160; INTERFERON TYPE II; INTERLEUKIN-2; LACTIC ACID; MICE; MICE, INBRED BALB C; PLASMIDS; POLYGLYCOLIC ACID; POLYMERS; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION; VACCINES, DNA; VACCINES, SYNTHETIC; VACCINIA VIRUS;

EID: 0037203925     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00480-7     Document Type: Article

References (54)

1. Human immunodeficiency virus type 1 infection, mucosal immunity, and pathogenesis and extramural research programs at the National Institutes of Health
2. HIV-1 induces cytotoxic T-lymphocytes in the cervix of infected women
3. Direct ex vivo simian immunodeficiency virus (SIV)-specific cytotoxic activity detected from small intestine intraepithelial lymphocytes of SIV-infected macaques at an advanced stage of infection
4. Selective induction of protective MHC class I-restricted CTL in the intestinal lamina propria of rhesus monkeys by transient SIV infection of the colonic mucosa
5. Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: Inverse relationship of degree of protection with level of attenuation
6. 2 antibody responses
7. Mucosal immunity and tolerance: Relevance to vaccine development
8. Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein
9. In defense of mucosal surfaces: Development of novel vaccines for IgA responses protective at the portals of entry of microbial pathogens
10. Targeting and controlled release of antigens for the effective induction of secretory antibody response
11. Protective immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles
12. Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses
13. Poly(DL-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration
14. Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza
15. Mucosal and systemic immune responses after oral delivery of vaccinia virus recombinants
16. Targeting of natural killer cells to mammary carcinoma via naturally occurring tumor cell-bound iC3b and β-glucan-primed CR3 (CD11b/CD18)
17. Soluble β-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells
18. The effect of yeast polysaccharides on mouse tumors
19. Comparative tumor-inhibitory and anti-bacterial activity of soluble and particulate glucan
20. Analysis of the sugar specificity and molecular location of the β-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18)
21. Mushrooms, tumors, and immunity
22. β(1-3)-glucan-mediated augmentation of alloreactive murine cytotoxic T-lymphocytes in vivo
23. Lentinan and its related polysaccharides as host defense potentiators: Their application to infectious diseases and cancer
24. Potentiation of host resistance against microbial infections by lentinan and its related polysaccharides
25. Lentinan potentiates immunity and prolongs the survival time of some patients
26. Clinical efficacy of lentinan on neoplastic diseases
27. Controlled trial of interleukin-2 infusions in patients with the human immunodeficiency virus
28. Systemic immunological effects of cytokine genes injected into skeletal muscle
29. Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2
30. Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration
31. A chimeric IL-2/Ig molecule possesses the functional activity of both proteins
32. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
33. Antitumor activity of lentinan in murine syngeneic and autochthonous hosts and its suppressive effect on 3-methylcholanthrene-induced carcinogenesis
34. Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: Analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses
35. Vaccinia virus: A selectable eukaryotic cloning and expression vector
36. Genetically engineered poxviruses for recombinant gene expression, vaccination and safety
37. Improved cationic lipid formulations for in vivo gene therapy
38. Fate of protein-containing liposomes injected into rats: An approach to the treatment of storage diseases
39. Effectiveness of liposomes possessing surface-linked recombinant B subunit of cholera toxin as an oral antigen delivery system
40. Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T-lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge
41. Mucosal immunity to HIV-1: Systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A)
42. + cytotoxic T-lymphocytes by free antigenic peptide: A self-veto mechanism?
43. Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1
44. Role of the V2, V3, and CD4-binding domains of gp120 in curdlan sulfate neutralization sensitivity of HIV-1 during infection of T-lymphocytes
45. The nature of viruses
46. Design and analysis of factorial experiments
47. Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus
48. Migration kinetics and final destination of type 1 and type 2 CD8 effector cells predict protection against pulmonary virus infection
49. Effective induction of simian immunodeficiency virus-specific cytotoxic T-lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen
50. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine
51. Induction of genital immunity by DNA priming and intranasal booster immunization with a replication-defective adenoviral recombinant
52. Cationic liposomes are a strong adjuvant for a DNA vaccine of human immunodeficiency virus type 1
53. Membrane complement receptors
54. The β-glucan-binding lectin site of mouse CR3 (CD11/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells